U.S. Oil and Gas Stock News

NasdaqGM:ISTR
NasdaqGM:ISTRBanks

Is Investar Holding Still Trading Below Fair Value After Its Strategic Acquisition?

Ever wondered if Investar Holding is trading for less than it’s really worth? Let’s dig into what the numbers and market buzz reveal about its current value. The stock has climbed 3.4% over the past month and is up 11.9% since the start of the year, signaling renewed investor interest and possibly shifting sentiment around its growth prospects. Recently, the company completed a strategic acquisition aimed at expanding its regional presence, which has caught the eye of both analysts and...
NasdaqCM:ELDN
NasdaqCM:ELDNBiotechs

Can Eledon Pharmaceuticals’ (ELDN) Mixed Kidney Trial Results Reshape Its Competitive Edge in Transplant Care?

In November 2025, Eledon Pharmaceuticals presented results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in kidney transplant recipients at the American Society of Nephrology's Kidney Week Annual Meeting. Although the primary endpoint did not meet statistical significance, the drug showed a promising safety profile and higher kidney function in some key patient subgroups compared to standard tacrolimus therapy. We'll explore how tegoprubart's...
NasdaqGS:AKRO
NasdaqGS:AKROBiotechs

Evaluating Akero Therapeutics (AKRO): Is the Current Valuation Justified After Recent Share Price Momentum?

Akero Therapeutics (AKRO) stock has been quietly trending higher this month, gaining roughly 16% despite little in the way of major news. Many investors are revisiting the company’s progress and recent momentum. See our latest analysis for Akero Therapeutics. Akero’s impressive 16% share price return this month builds on a strong year, with momentum clearly gaining steam. The stock has surged 92.5% year-to-date. While recent news has been quiet, long-term total shareholder returns have also...